Quidel Corporation develops, manufactures and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases and toxicology worldwide.
The company during 2020 benefited greatly from the pandemic thanks to its Covid-19 QuickVue test that recently received FDA authorization to apply it from house to home.
The company is optimistic about the Biden Administration's urgent and comprehensive approach to bringing the benefits of rapid, routine, and equitable coronavirus testing to U.S. classrooms, under-neglected communities, and rural areas.
- Sales Y/Y 210%
- EBITDA Y/Y 628%
- Net income Y/Y 1010%
Technical:
- Low RSI levels
- Bounce on MA100
- Support $128
The company during 2020 benefited greatly from the pandemic thanks to its Covid-19 QuickVue test that recently received FDA authorization to apply it from house to home.
The company is optimistic about the Biden Administration's urgent and comprehensive approach to bringing the benefits of rapid, routine, and equitable coronavirus testing to U.S. classrooms, under-neglected communities, and rural areas.
- Sales Y/Y 210%
- EBITDA Y/Y 628%
- Net income Y/Y 1010%
Technical:
- Low RSI levels
- Bounce on MA100
- Support $128
Trade fechado: stop atingido:
26 Mar